Skip to content
The Chat Archive
sonar-reasoning-pro-high· Perplexity LMArena Search Arena 24K

Who owns the rights to linzess, Abbvie or Ironwood? What happens to Ironwood’s rights to…

  1. User

    Who owns the rights to linzess, Abbvie or Ironwood? What happens to Ironwood’s rights to Linzess when the product goes generic?

  2. Assistant

    Ironwood Pharmaceuticals and AbbVie currently co-own the rights to Linzess (linaclotide) through a collaborative partnership. Under their agreement, they co-develop and co-commercialize Linzess in the United States[1][3]. The specific terms of their collaboration include a 50/50 profit-sharing arrangement, where Ironwood receives 50% of the net profits and bears 50% of the net losses from Linzess sales in the U.S.[2][5]

    This partnership extends beyond just revenue sharing, as both companies jointly manage various aspects of the drug's commercialization. For example, in their financial reporting, Ironwood stated that "LINZESS net sales are reported by AbbVie and LINZESS costs incurred by each of us and AbbVie are reported in our respective financial statements"[5].

    For territories outside the United States, the arrangements vary:

    • In China, Ironwood has partnered with AstraZeneca for development and commercialization[9]
    • For other global territories, Ironwood has partnered with AbbVie[9]

    Patent Protection and Generic Timeline

    Regarding what happens when Linzess goes generic, the companies have already established a framework through settlement agreements with several generic manufacturers. Currently, there is no generic version of Linzess available in the United States[6]. The drug is protected by multiple patents, with expiration dates ranging from 2031 to 2033[6].

    However, Ironwood and AbbVie (previously Allergan, which was acquired by AbbVie) have reached settlements with several generic manufacturers:

    • Teva: Licensed to market generic versions (145 mg and 290 mg) starting March 31, 2029[7]
    • Mylan: Licensed for 145 mg and 290 mg doses from February 5, 2030, and 72 mg dose from August 5, 2030[7]
    • Sandoz: Can market generic versions from February 2030[7]
    • Aurobindo: Licensed to market generic version from August 5, 2030[7][8]

    These settlement agreements essentially determine when Ironwood's exclusive rights (shared with AbbVie) will begin to diminish. While the patents technically extend to 2031-2033, these negotiated settlements allow for earlier generic entry, beginning in 2029 with Teva.

    When these generic versions enter the market, Ironwood will likely see a significant reduction in its revenue from Linzess as market share shifts to lower-priced alternatives, though they will still retain their intellectual property rights to the original branded product.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.